The purpose of this study is to test whether a new drug regimen will reduce the chances of side effects but be just as effective as the usual treatment for HER2-positive, ER-negative and node negative breast cancer.
MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)
A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Oral presentation by Dr Laura Dawson at the ASCO Gastrointestinal Cancer Symposium 2023 of results for the CCTG HE1 phase III study of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver metastases.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)
PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)
Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)
A Phase II Pre-operative Trial of JDQ433 in Surgically Resectable NSCLC
Adjuvant Treatment Guided by Response Post Neoadjuvant Therapy for Stage III Melanoma
Evaluating the Impact of SBRT with or without Nirapariib in Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy
Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment (ASCENDE-SBRT)
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes
The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS
STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study
Canadian Neuroendocrine Tumour Society (CNETS) 2022 Research Grant Award to support Canadian participation in STOPNET international trial. STOPNET is a Randomized Study of Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine Tumours.
This trial will investigate whether it is worthwhile for neuroendocrine tumor (NET) patients to continue somatostatin analogue (SSA) therapy after treatment with peptide radionuclide therapy (PRRT). The study proposes to stop SSA injections for some patients following PRRT in order for researchers to compare tumour growth, side effects and quality of life with patients who continue SSA injections.
“It is unclear whether patients with neuroendocrine tumours requiring Peptide Receptor Radionuclide Therapy (PRRT) gain additional benefit from continued use of somatostatin analoque (SSA) drugs, or whether their side effects, expense and inconvenience can be safely avoided,” says CCTG Senior Investigator Chris O’Callaghan. “The STOPNET clinical trial is a first step toward addressing what is an important question for all of patients, physicians and healthcare funders.”
Neuroendocrine tumors (NET) usually begin in specialized cells called neuroendocrine cells, similar to nerve cells or hormone-producing cells. However, approximately 75% of NETs do not result in hormone overproduction and the main treatment for both is SSA, which slows tumour growth and reduce hormone production. Unfortunately, the majority of patients will experience tumour growth despite SSA therapy. When this occurs, PRRT is added in combination with ongoing SSA therapy but it is not known if continuing SSA therapy after PRRT is beneficial or not. The study hopes to support the best care options and quality of life for NETs patients.
The funding will support the Canadian participation in Australasian Gastrointestinal Trials Group (AGITG)-led STOPNET trial with support from NeuroEndocrine Cancer Australia and CNETs Canada.
Congratulations to Dr. Vasconcelos, a BC Cancer GI Medical Oncology Fellow, was selected by the CCTG review committee to be awarded the The Frances A Shepherd Award for his abstract: Transverse colon primary analysis for CO20 and CO17 which was selected for the ASCO Gastrointestinal Cancers Symposium.
CCTG HN11 SELECT has now opened to accrual across Canada and sites in the US. The trial is a randomized, controlled, phase III clinical trial for patients with lateralized oropharyngeal carcinoma (OPC)
A new Canadian trial designed and led by Sunnybrook Health Sciences Centre will determine whether Stereotactic Ablative Body Radiotherapy (SABR) can replace the standard brachytherapy boost for men with unfavourable risk prostate cancer.
Three CCTG trials were recently awarded nearly $7.5M from the Canadian Institutes of Health Research (CIHR) 2022 Spring Project Grant competition.
The recently launched Centre for Health Innovation, aims to connect researchers from across multiple disciplines to tackle the most pressing human health challenges. A critical part of the centre will be a new home for the CCTG Tumour Tissue Data Repository and includes a large-scale expansion of its histopathology and biobanking resources.
Liquid-Biopsy Monitoring for Patients not yet Eligible for Screening and Enrollment
De-escalation of Chemo in HER-2+, ER-, Node-negative, breast cancer patients who achieved complete response after chemo and Dual HER-2 blOckade (DECRESCENDO)
Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied.
CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.
The establishment of the Britton Smith Foundation Clinical Trials Fund. A thank you from Doug Kane, senior manager, Canadian Cancer Society FLA & The Waterways Community Office.
Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.
“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”
Translational Lung Cancer Research 10: 826 - 838, 21 FFung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;
J Clin Oncol 41: TPS259 - TPS259, 2023Morris VK;Yothers G;Kopetz S;Jacobs SA;Lucas PC;Iqbal A;Boland PM;Deming DA;Scott AJ;Lim HJ;Hong TS;Wolmark N;George TJ;
J Clin Oncol 41: TPS260 - TPS260, 2023Lieu CH;Lin Y;Kopetz S;Jacobs SA;Lucas PC;Sahin IH;Deming DA;Philip PA;Hong TS;Rojas-Khalil Y;Loree JM;Wolmark N;Yothers G;George TJ;Dasari A;
J Clin Oncol 41: 124 - 124, 2023Solar Vasconcelos JP;Chen N;Tu D;Brule SY;Goodwin RA;Jonker DJ;Price TJ;Zalcberg JR;Moore MJ;Karapetis CS;Siu LL;Shapiro JD;Simes J;O'Callaghan CJ;Loree JM;
J Clin Oncol 41: 180 - 180, 2023Loree JM;Madison R;O'Callaghan CJ;Brown CJ;Tu D;Jonker DJ;Sherry M;Fine AD;Huang Y;Camara W;Pokharel P;Aleshin A;Oxnard GR;Kennecke HF;
J Clin Oncol 41: 183 - 183, 2023Ma LX;Loree JM;Jonker DJ;Kennecke HF;Berry SR;Couture F;Ahmad CE;Goffin JR;Kavan P;Harb M;Colwell B;Samimi S;Samson B;Abbas T;Aucoin N;Aubin F;Koski SL;Tu D;O'Callaghan CJ;Chen EX;
J Clin Oncol 41: LBA294 - LBA294, 2023Pavlakis N;Shitara K;Sjoquist KM;Martin AJ;Jaworski A;Yip S;Bang YJ;Alcindor T;O'Callaghan CJ;Tebbutt NC;Strickland A;Rha SY;Lee KW;Zalcberg JR;Price TJ;Simes J;Goldstein D;
J Clin Oncol 41: LBA492 - LBA492, 2023Dawson LA;Fairchild AM;Dennis K;Mahmud A;Stuckless TL;Vincent F;Roberge D;Follwell M;Wong RKW;Jonker DJ;Knox JJ;Zimmermann C;Wong P;Purdie T;Ringash J;Barry AS;Gaudet M;Tu D;Wong RK;O'Callaghan CJ;
